Target
Connective Tissue Growth Factor
Description
Anti-Connective Tissue Growth Factor Antibody, Non-Fucosylated (BioBet-751ZP) is a human monoclonal IgG antibody against Connective Tissue Growth Factor. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Idiopathic pulmonary fibrosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Connective Tissue Growth Factor antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
connective tissue growth factor
Background
The protein encoded by this gene is a mitogen that is secreted by vascular endothelial cells. The encoded protein plays a role in chondrocyte proliferation and differentiation, cell adhesion in many cell types, and is related to platelet-derived growth factor. Certain polymorphisms in this gene have been linked with a higher incidence of systemic sclerosis.
Alternative Names
CTGF; connective tissue growth factor; CCN2; NOV2; HCS24; IGFBP8; IBP-8; IGFBP-8; CCN family member 2; IGF-binding protein 8; hypertrophic chondrocyte-specific protein 24; insulin-like growth factor-binding protein 8
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with CCN2 include Renal Fibrosis and Systemic Scleroderma.
Related Pathways
Its related pathways are NF-KappaB Family Pathway and amb2 Integrin signaling.
Function
The main connective tissue mitotic attractant secreted by vascular endothelial cells. Promote the proliferation and differentiation of chondrocytes. Mediates heparin and divalent cation-dependent cell adhesion to many cell types, including fibroblasts, myofibroblasts, endothelial cells and epithelial cells. Enhance DNA synthesis induced by fibroblast growth factor.
Post-translational modifications
1.Glycosylation at Asn28, Thr193, and Asn225 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
FG-3019 is an investigational therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The clinical studies of FG-3019 in idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis show that, it has been well tolerated, with no apparent safety signals, in more than ten clinical studies and more than 340 treated patients to date.
Antibody Indication
Idiopathic pulmonary fibrosis
